SLU-915
SLU-915, more formally SLU-PP-915, is a follow-up compound to SLU-PP-332 developed to improve oral bioavailability while keeping the same core mechanism: activating the estrogen-related receptor family as a proposed exercise mimetic. It remains entirely preclinical, studied only in mice, with no human trials.
- Classification
- Pan-ERR agonist (synthetic small molecule)
- Half-Life
- Not well established in published data
- Format
- Capsule
What Is SLU-915?
SLU-915 was developed as a next-generation version of SLU-PP-332, the original pan-ERR agonist studied for exercise-mimetic effects. Its main design goal was improved oral bioavailability, meaning the compound survives digestion and reaches active circulation more effectively when taken by mouth.
Like SLU-PP-332, SLU-915 targets ERRα, ERRβ, and ERRγ, a family involved in mitochondrial biogenesis and energy metabolism. Its research history is shorter and thinner because it is newer and has fewer published studies.
What SLU-915 Is Being Researched For
Gene Expression and Metabolic Effects in Mice
Research has examined SLU-915's effects on gene expression and receptor activity in cell-based assays and mouse models, building on the ERR-activation framework established for SLU-PP-332.
Comparative Pharmacology Research
A recent analytical chemistry study characterized the in vitro metabolism of SLU-PP-332 and SLU-915 together, partly because of their potential relevance to sports anti-doping testing.[1]
How SLU-915 Works
Activating the Same ERR Family as SLU-PP-332
Research points to SLU-915 targeting all three ERR isoforms, triggering downstream effects on mitochondrial biogenesis and fatty acid oxidation genes.[1]
Improved Oral Bioavailability as the Key Design Change
The main distinction from SLU-PP-332 is pharmacokinetic rather than mechanistic: SLU-915 was engineered to be absorbed and remain active more effectively when taken orally.
Reconstitution and Handling
SLU-915 is typically supplied in capsule form for oral research use. Capsules should be stored in a cool, dry place away from direct light and handled according to the specific product's labeling since formulations can vary by supplier.
Key Takeaways
SLU-915 represents a pharmacokinetic follow-up to SLU-PP-332 rather than a mechanistically distinct compound. Its own research base is considerably thinner, and no human trials have been conducted. Rodent exercise-mimetic findings should not be assumed to translate directly to people.
Frequently Asked Questions
What is SLU-915 derived from?
It's a fully synthetic small molecule developed as a follow-up to SLU-PP-332 with the same core ERR-activating mechanism.
How is SLU-915 different from SLU-PP-332?
The main difference is improved oral bioavailability. Both compounds target the same estrogen-related receptor family.
What has SLU-915 been studied for?
Research has examined gene expression and metabolic effects in mouse models, along with comparative pharmacology and in vitro metabolism.
Has SLU-915 been tested in humans?
No. No human clinical trials have been conducted or registered for this compound.
Should results from SLU-PP-332 be expected to transfer?
Not automatically. The shared mechanism makes similar effects plausible, but SLU-915 has a much smaller dedicated research base.
Sources and Research
- Möller T, Krug O, Thevis M. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid Commun Mass Spectrom. 2026.
Related Reading
For educational and research purposes only. Not medical advice. Always consult a licensed healthcare professional before starting any protocol.